A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study

Terzah M. Horton; Richard A. Drachtman; Lu Chen; Peter D. Cole; Kathleen Mccarten; Stephan Voss; Robert P. Guillerman; Allen Buxton; Scott C. Howard; Shirley M. Hogan; Andrea M. Sheehan; Dolores López-Terrada; Matthew D. Mrazek; Neeraj Agrawal; Meng Fen Wu; Hao Liu; Pedro A. De Alarcon; Tanya M. Trippet; Cindy L. Schwartz

doi:10.1111/bjh.13388

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study

Terzah M. Horton, Richard A. Drachtman, Lu Chen, Peter D. Cole, Kathleen Mccarten, Stephan Voss, Robert P. Guillerman, Allen Buxton, Scott C. Howard, Shirley M. Hogan, Andrea M. Sheehan, Dolores López-Terrada, Matthew D. Mrazek, Neeraj Agrawal, Meng Fen Wu, Hao Liu, Pedro A. De Alarcon, Tanya M. Trippet, Cindy L. Schwartz

Pediatrics

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.

Original language	English (US)
Pages (from-to)	118-122
Number of pages	5
Journal	British Journal of Haematology
Volume	170
Issue number	1
DOIs	https://doi.org/10.1111/bjh.13388
State	Published - Jul 1 2015

Keywords

Childhood haematological malignancies
Clinical trials
NF-κB
Paediatric oncology

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.13388

Cite this

Horton, T. M., Drachtman, R. A., Chen, L., Cole, P. D., Mccarten, K., Voss, S., Guillerman, R. P., Buxton, A., Howard, S. C., Hogan, S. M., Sheehan, A. M., López-Terrada, D., Mrazek, M. D., Agrawal, N., Wu, M. F., Liu, H., De Alarcon, P. A., Trippet, T. M., & Schwartz, C. L. (2015). A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study. British Journal of Haematology, 170(1), 118-122. https://doi.org/10.1111/bjh.13388

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study. / Horton, Terzah M.; Drachtman, Richard A.; Chen, Lu et al.
In: British Journal of Haematology, Vol. 170, No. 1, 01.07.2015, p. 118-122.

Research output: Contribution to journal › Article › peer-review

Horton, TM, Drachtman, RA, Chen, L, Cole, PD, Mccarten, K, Voss, S, Guillerman, RP, Buxton, A, Howard, SC, Hogan, SM, Sheehan, AM, López-Terrada, D, Mrazek, MD, Agrawal, N, Wu, MF, Liu, H, De Alarcon, PA, Trippet, TM & Schwartz, CL 2015, 'A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study', British Journal of Haematology, vol. 170, no. 1, pp. 118-122. https://doi.org/10.1111/bjh.13388

@article{4051b993f2b04647bc4a4a28fafef20d,

title = "A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study",

abstract = "A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.",

keywords = "Childhood haematological malignancies, Clinical trials, NF-κB, Paediatric oncology",

author = "Horton, {Terzah M.} and Drachtman, {Richard A.} and Lu Chen and Cole, {Peter D.} and Kathleen Mccarten and Stephan Voss and Guillerman, {Robert P.} and Allen Buxton and Howard, {Scott C.} and Hogan, {Shirley M.} and Sheehan, {Andrea M.} and Dolores L{\'o}pez-Terrada and Mrazek, {Matthew D.} and Neeraj Agrawal and Wu, {Meng Fen} and Hao Liu and {De Alarcon}, {Pedro A.} and Trippet, {Tanya M.} and Schwartz, {Cindy L.}",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons Ltd.",

year = "2015",

month = jul,

day = "1",

doi = "10.1111/bjh.13388",

language = "English (US)",

volume = "170",

pages = "118--122",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma

T2 - A Children's Oncology Group study

AU - Horton, Terzah M.

AU - Drachtman, Richard A.

AU - Chen, Lu

AU - Cole, Peter D.

AU - Mccarten, Kathleen

AU - Voss, Stephan

AU - Guillerman, Robert P.

AU - Buxton, Allen

AU - Howard, Scott C.

AU - Hogan, Shirley M.

AU - Sheehan, Andrea M.

AU - López-Terrada, Dolores

AU - Mrazek, Matthew D.

AU - Agrawal, Neeraj

AU - Wu, Meng Fen

AU - Liu, Hao

AU - De Alarcon, Pedro A.

AU - Trippet, Tanya M.

AU - Schwartz, Cindy L.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.

AB - A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.

KW - Childhood haematological malignancies

KW - Clinical trials

KW - NF-κB

KW - Paediatric oncology

UR - http://www.scopus.com/inward/record.url?scp=84931563104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931563104&partnerID=8YFLogxK

U2 - 10.1111/bjh.13388

DO - 10.1111/bjh.13388

M3 - Article

C2 - 25833390

AN - SCOPUS:84931563104

SN - 0007-1048

VL - 170

SP - 118

EP - 122

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: A Children's Oncology Group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this